Chen, Ziqing
Kang, Yibin
Article History
Received: 2 September 2022
Revised: 28 November 2022
Accepted: 5 December 2022
First Online: 9 January 2023
Competing interests
: Y.K. is a founder, scientific advisory board member, and shareholder of KayoThera and Firebrand Therapeutics. Y.K. is one of the Associate Editors of Signal Transduction and Targeted Therapy, but he has not been involved in the process of the manuscript handling.